iTeos' Small-Molecule Approach Adds to Immunotherapy Arsenal
Nearly 20 years of work in cancer immunotherapy finally scored two big regulatory wins in recent years, with the approvals of Dendreon Corp.'s prostate cancer vaccine Provenge (sipuleucel-T) and Bristol-Myers Squibb Co.'s melanoma drug Yervoy (ipilimumab), but there is plenty of room for new approaches before the immunotherapy space reaches its full potential.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST